Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

@article{Siemers2010SafetyAC,
  title={Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.},
  author={Eric R. Siemers and Stuart Friedrich and R. A. Dean and Celedon R. Gonzales and Martin R. Farlow and Steven M Paul and Ronald Bradley Demattos},
  journal={Clinical neuropharmacology},
  year={2010},
  volume={33 2},
  pages={67-73}
}
OBJECTIVES Active and passive immunization strategies have been suggested as possible options for the treatment of Alzheimer disease (AD). LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD. METHODS Patients with mild to moderate AD were screened and selected for inclusion. Initial screening was performed for 54 subjects, and 29 of these underwent additional screening; after this second screening, a total of 19 subjects… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 81 extracted citations

Similar Papers

Loading similar papers…